Transcriptomic characterization of control and drug-treated APOB-mutant organoids to study steatosis-resolving drug effects

We treated APOB-mutant organoids with different anti-NAFLD drug candidates that were effective at resolving steatosis. To understand the mechanisms of drug action and adverse drug effects we performed bulk RNA-sequencing on drug-treated and vehicle-treated APOB mutant organoids. APOB-mutant organoids, 2 clonal lines from 2 different donors, were treated with the respective drug (ACCi, FASi, DGAT2i, FXRa, or hFGF19) or vehicle (control) for 7 days. Thereafter, organoids were harvested for RNA extraction.